Get the Stockscreener App
3.25
5.86%
0.18
After Hours:
3.22
-0.03
-0.92%
Abvc Biopharma Inc stock is traded at $3.25, with a volume of 215.29K.
It is up +5.86% in the last 24 hours and up +57.77% over the past month.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
See More
Previous Close:
$3.07
Open:
$3.09
24h Volume:
215.29K
Relative Volume:
0.51
Market Cap:
$55.19M
Revenue:
$152.40K
Net Income/Loss:
$-10.52M
P/E Ratio:
-1.3036
EPS:
-2.4931
Net Cash Flow:
$-4.26M
1W Performance:
-9.22%
1M Performance:
+57.77%
6M Performance:
+520.70%
1Y Performance:
+343.99%
1-Day Range:
$3.09
$3.39
1-Week Range:
$2.95
$3.60
52-Week Range:
$0.40
$5.48
Abvc Biopharma Inc Stock (ABVC) Company Profile
Name
Abvc Biopharma Inc
Sector
Industry
Phone
510-668-0881
Address
44370 OLD WARM SPRINGS BLVD., FREMONT
Compare ABVC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABVC
Abvc Biopharma Inc
|
3.25 | 52.13M | 152.40K | -10.52M | -4.26M | -2.4931 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Abvc Biopharma Inc Stock (ABVC) Latest News
What drives ABVC BioPharma Inc. stock priceGame-changing capital returns - Autocar Professional
ABVC BioPharma Strengthens Oncology Partnership With $100,000 Milestone Payment From OncoX BioPharma - Yahoo Finance
Is ABVC BioPharma Inc. a good long term investmentConsistent double returns - jammulinksnews.com
Sixteen new option listings on July 23rd - TipRanks
ABVC BioPharma Inc Inc. (ABVC) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
What analysts say about ABVC BioPharma Inc. stockStrong return on assets - jammulinksnews.com
Is ABVC BioPharma Inc. stock a growth or value playAlpha Stock Ideas - Newser
ABVC BioPharma Inc. Stock Analysis and ForecastFree Advanced Stock Screener Access - jammulinksnews.com
What makes ABVC BioPharma Inc. stock attractive to long term investorsValue Pick Scanner - Newser
ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program - Yahoo Finance
What makes ABVC BioPharma Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
Why ABVC BioPharma Inc. stock attracts strong analyst attentionDaily Gain Forecast - Newser
How ABVC BioPharma Inc. stock performs during market volatilityFree Exclusive Access to Stock Gurus - Newser
ABVC BioPharma Soars 16%—Is This the Breakout Biotech Investors Have Been Waiting For? - AInvest
ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships - Yahoo Finance
ABVC BioPharma CEO Dr. Uttam Patil Recognized Among Elite Indian-Origin CEOs Making Global Impact in Science and Technology - StreetInsider
ABVC BioPharma Converts Strategic Note Into Equity in AiBtl BioPharma; Commits to Up to $20 Million in Total Investment - Yahoo Finance
ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform to Strengthen Oncology Portfolio - citybuzz -
ABVC BioPharma Expands Oncology Portfolio as Affiliate OncoX Acquires Patented Lycopenoid Platform Valued at $4.06 Million - The Globe and Mail
ABVC BioPharma Shareholders Approve Key Proposals - TipRanks
Abvc Biopharma Inc Stock (ABVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.32%
1.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):